​

Y-mAbs Therapeutics Ownership | Who Owns Y-mAbs Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Y-mAbs Therapeutics Ownership Summary

Y-mAbs Therapeutics is owned by 56.98% institutional investors, 12.44% insiders, and 30.58% retail investors. Paradigm biocapital advisors lp is the largest institutional shareholder, holding 9.49% of YMAB shares. HBM Healthcare Investments AG Ord is the top mutual fund, with 7.36% of its assets in Y-mAbs Therapeutics shares.

YMAB Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockY-mAbs Therapeutics56.98%12.44%30.58%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Paradigm biocapital advisors lp4.24M9.49%$33.17M
Blackrock funding, inc. /de3.00M6.72%$23.48M
Blackrock2.94M6.71%$35.50M
Sofinnova investments2.19M4.92%$17.18M
Vanguard group2.00M4.48%$15.66M
Polar capital1.83M4.18%$22.12M
Caligan partners lp1.77M3.96%$13.84M
Logos global management lp1.00M2.24%$7.83M
Geode capital management822.31K1.84%$6.44M
State street804.61K1.84%$9.72M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Caligan partners lp1.77M3.51%$13.84M
Sofinnova investments2.19M1.25%$17.18M
Paradigm biocapital advisors lp4.24M1.15%$33.17M
Logos global management lp1.00M0.92%$7.83M
Cormorant asset management, lp425.00K0.18%$3.33M
Soleus capital management349.98K0.17%$2.74M
Boothbay fund management693.69K0.13%$5.43M
Polar capital1.83M0.13%$22.12M
Virtus etf advisers35.79K0.11%$280.23K
Rice hall james & associates108.55K0.05%$849.94K

Top Buyers

HolderShares% AssetsChange
Caligan partners lp1.77M3.51%572.73K
Logos global management lp1.00M0.92%200.00K
Paradigm biocapital advisors lp4.24M1.15%150.00K
Boothbay fund management693.69K0.13%136.26K
Renaissance131.60K0.00%103.70K

Top Sellers

HolderShares% AssetsChange
Cormorant asset management, lp425.00K0.18%-1.02M
D. e. shaw615.13K0.00%-172.41K
Los angeles capital management---127.55K
Acadian asset management---105.78K
Point72 asset management550.00--94.83K

New Positions

HolderShares% AssetsChangeValue
Jump financial33.38K0.01%33.38K$261.37K
Exoduspoint capital management, lp32.26K0.00%32.26K$253.00K
Susquehanna group, llp28.49K-28.49K$223.07K
Engineers gate manager lp27.39K0.00%27.39K$214.43K
Proshare advisors12.64K0.00%12.64K$99.01K

Sold Out

HolderChange
Capital performance advisors llp-3.00
Nelson, van denburg & campbell wealth management group-8.00
Allspring global investments-8.00
Parallel advisors-18.00
Advisor group-30.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024107-0.93%25,429,341-1.21%561.71%52-8.77%3110.71%
Sep 30, 202410811.34%25,741,8205.70%571.88%5711.76%28-20.00%
Jun 30, 202496-3.03%24,352,7925.85%552.00%5113.33%34-20.93%
Mar 31, 2024996.45%23,007,88413.95%522.46%45-4.26%4338.71%
Dec 31, 202393-5.10%20,191,0852.81%462.29%4720.51%31-16.22%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
HBM Healthcare Investments AG Ord3.30M7.36%-
Polar Capital Biotech S Inc1.50M3.32%-
Vanguard Total Stock Mkt Idx Inv1.04M2.30%-
Vanguard US Total Market Shares ETF1.04M2.30%-
iShares Russell 2000 ETF970.46K2.15%-8.41K
Vanguard Institutional Extnd Mkt Idx Tr500.90K1.11%-
SPDR® S&P Biotech ETF438.23K0.97%-2.67K
Pictet Biotech390.64K0.88%390.64K
Pictet-Biotech P USD390.47K0.86%-720.00
Fidelity Small Cap Index367.83K0.81%-6.89K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 07, 2025Rossi Michael J PRESIDENT & CEOSell$20.37K
Mar 07, 2025Gad Thomas CHIEF BUSINESS OFFICERSell$56.54K
Sep 13, 2024Gad Thomas CHIEF BUSINESS OFFICERSell$875.55K
Sep 16, 2024Gad Thomas CHIEF BUSINESS OFFICERSell$389.10K
Aug 28, 2024Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICERSell$768.50K

Insider Transactions Trends

DateBuySell
2024 Q3-4
2024 Q2-7
2024 Q1-3
2023 Q4145
2023 Q22-

YMAB Ownership FAQ

Who Owns Y-mAbs Therapeutics?

Y-mAbs Therapeutics shareholders are primarily institutional investors at 56.98%, followed by 12.44% insiders and 30.58% retail investors. The average institutional ownership in Y-mAbs Therapeutics's industry, Biotech Stocks , is 68.48%, which Y-mAbs Therapeutics falls below.

Who owns the most shares of Y-mAbs Therapeutics?

Y-mAbs Therapeutics’s largest shareholders are Paradigm biocapital advisors lp (4.24M shares, 9.49%), Blackrock funding, inc. /de (3M shares, 6.72%), and Blackrock (2.94M shares, 6.71%). Together, they hold 22.92% of Y-mAbs Therapeutics’s total shares outstanding.

Does Blackrock own Y-mAbs Therapeutics?

Yes, BlackRock owns 6.71% of Y-mAbs Therapeutics, totaling 2.94M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 35.5M$. In the last quarter, BlackRock increased its holdings by 81.46K shares, a 2.85% change.

Who is Y-mAbs Therapeutics’s biggest shareholder by percentage of total assets invested?

Caligan partners lp is Y-mAbs Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.51% of its assets in 1.77M Y-mAbs Therapeutics shares, valued at 13.84M$.

Who is the top mutual fund holder of Y-mAbs Therapeutics shares?

HBM Healthcare Investments AG Ord is the top mutual fund holder of Y-mAbs Therapeutics shares, with 7.36% of its total shares outstanding invested in 3.3M Y-mAbs Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools